Hamideh Safi-Aghdam - The Consciousness Library

Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.

Scientific Reports April 17, 2024 Jordan Sloshower, Richard J. Zeifman, Jeffrey Guss et al. 56 citations

Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests that improvements in psychological flexibility may mediate therapeutic...

DOI: 10.1038/s41598-024-58318-x Full text Mental health treatment Depression research Mindfulness-based therapy Psilocybin therapy +1

Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms

Journal of Psychopharmacology June 30, 2023 Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al. 47 citations

Background: Evidence suggests that serotonergic psychedelics (e.g. psilocybin), have rapid-acting and long-lasting antidepressant effects after a single dose. However, the mechanism underlying these effects remain unclear. One proposed mechanism is that these drugs promote neuroplasticity. However, this has not been conclusively demonstrated in humans. Aims: We hypothesized that relative to...

DOI: 10.1177/02698811231179800 Psilocybin Neuroplasticity Electroencephalography Antidepressant +3

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial

Journal of Psychopharmacology March 20, 2023 Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al. 153 citations

Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature. Methods: In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with...

DOI: 10.1177/02698811231154852 Psilocybin Major depressive disorder Anxiety Placebo +5

Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology September 1, 2022 Deepak Cyril D'Souza, Shariful A. Syed, L Taylor Flynn et al. 156 citations

There is considerable interest in the therapeutic potential of psychedelic drugs. Dimethyltryptamine (DMT) is a potent, rapid-onset, and short-acting psychedelic drug that has not yet been independently tested for the treatment of depression. The safety, tolerability, and efficacy of intravenous DMT were investigated in treatment-resistant individuals with major depressive disorder (MDD) and...

DOI: 10.1038/s41386-022-01344-y Full text Psychedelic therapy Treatment-resistant depression Depressive disorder Rapid-onset psychedelic +22

Papers

Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.

Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial

Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder.